and 2.13 [1. 75 -2.59] in G3 compared to G1. In multivariate analysis, pain at randomization was the strongest predictor of poor OS: HR 1.71, 95% CI 1.39-2.11, vs PSA progression only. Other significant prognostic factors included older age, high alkaline phosphatase, short duration of first androgen deprivation therapy, low hemoglobin level and high neutrophil-lymphocyte ratio. Docetaxel led to 50% decline in PSA in 67.5%, 80.5% and 77% in G1, G2 and G3 respectively. Conclusions: The type of progression at initiation of first-line chemotherapy in mCRPC is prognostic. Patients with pain at initiation of chemotherapy had a median OS of 1 year shorter than those having PSA progression only. Validation of these results by an independent dataset (TAX 327) is ongoing. Background: Platinum compounds have been tested in a larger number of mostly small to medium sized clinical trials in molecularly unselected prostate cancer patients (pts). Advances in castration-resistant prostate cancer (CRPC) molecular profiling have shown that a significant proportion of pts harbor DNA repair defects, which may serve as predictive markers for sensitivity to platinum agents. Our aim was to evaluate the antitumour activity of platinum agents in a contemporaneous mCRPC cohort with or without DNA repair defects. Methods: International, multicenter retrospective database project in 14 centers worldwide. Pts with mCRPC treated with a platinum agent were included. Pts with primary pure small cell carcinoma and/or insufficient outcome data were excluded. For antitumour activity PSA levels at baseline, after 4-, 8-and 12-weeks of therapy (tx) were analyzed as well as soft tissue response and duration of platinum-based chemotherapy. Overall survival (OS) was analyzed by Kaplan Meier method. Results: A total of 167 pts have been included in this analysis, 33 (20%) received platinum monotherapy, 134 (80%) a platinum combination therapy. Carboplatin was used in 140 (84%), cisplatin in 26 (16%) of pts. Combination tx with etoposise was used in 45 (27%), paclitaxel in 35 (21%) and docetaxel in 28 (17%) of pts. At start of platinum tx median age was 68 years, median PSA 78 ug/l, median ALP 185 U/l, median hemoglobin 103 g/l. The metastatic sites at start of platinum therapy were: bone 84%, lymph node 59% and visceral 60%. Outcome data by DNA repair defect status are summarized in the table.
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